MDWD
MediWound Ltd.
NASDAQ · Healthcare · Biotechnology · IL
$12.70
+7.17%Sep 22, 2026, 11:00 UTC
MediWound was awarded an additional $3.3 million by the U.S. Department of War to advance a room-temperature-stable formulation of NexoBrid.
Source:Sep 14, 2026, 11:00 UTC
MediWound announced that the independent Data and Safety Monitoring Board completed a pre-specified periodic safety review of the ongoing Phase III VALUE study of EscharEx in patients with venous leg ulcers and recommended the study continue without modification.
Source:Aug 13, 2026, 13:16 UTC
MediWound reported a Q2 2026 net loss of $0.77 per share, compared to a loss of $1.23 per share a year ago.